Business Wire

Kiwi.com Announces New Board of Directors as Company Enters Next Phase of Strategic Growth

Share

Kiwi.com, a leading online travel booking platform powered by cutting-edge technology, today announced a new Board of Directors to guide the Company through its next phase of growth.

Daniel Finnegan, former Chief Financial Officer and Chief Accounting Officer of Booking Holdings (formerly The Priceline Group Inc.), will serve as an independent Board Director. During Mr. Finnegan’s 14-year tenure with Booking Holdings, the company grew to about 22,000 employees and reached a valuation of more than $100 billion.

“I am excited for the opportunity to work with Oliver and the Kiwi team as they build towards ambitious goals that will ultimately provide extraordinary value and experiences to travelers worldwide,” said Daniel Finnegan.

Kiwi.com executives Oliver Dlouhý, Co-founder and CEO, and Juraj Striezenec, CFO, as well as General Atlantic Technology sector team members Tanzeen Syed, Managing Director, and Jessie Cai, Vice President, will also join the Board.

“I am grateful to be surrounded by a group of experts with whom I look forward to closely working as we scale Kiwi.com,” said Oliver Dlouhý. “Our new Board brings a diversity of strategic and operational experience spanning the technology and travel sectors, and Dan’s background as the former CFO of one of the world’s largest travel companies will be invaluable to our business. The creation of this team is an exciting milestone in this next chapter of our growth.”

In June 2019 Kiwi.com announced a strategic investment from General Atlantic, a leading global growth investor, to help scale the business and support management’s vision to create a seamless end-to-end travel experience for customers. General Atlantic has extensive experience in the global online travel industry, with current and past investments including Priceline, Airbnb, Meituan, Flixbus, Uber, Despegar.com, Smiles and Mafengwo.

Tanzeen Syed continued, “We believe the structure and expertise of this Board well-positions Kiwi.com to execute on its vision of creating a comprehensive travel experience for consumers around the globe. The addition of an independent Director of the caliber and experience level of Dan brings further momentum to the business as Kiwi.com enters this next phase of growth. General Atlantic is excited to be working alongside Oliver, the Board and the Kiwi.com team to continue building a next-generation travel technology platform.”

Kiwi.com, a rapidly growing technology company, was founded in 2012 and was recognized as the #1 fastest-growing Czech start-up by Forbes Magazine in 2017 and 2018. Through its proprietary technology and algorithms, Kiwi.com has a unique ability to offer expansive flight options to value-conscious consumers.

The Company pioneered technology that matches passengers to multiple carriers and flights on single itineraries and partners with airlines, online travel agencies, and metasearch engines to sell more than €1 billion in tickets across the globe.

About Kiwi.com

Kiwi.com was founded in 2012 by Oliver Dlouhý and Jozef Képesi. The travel tech company was created for travellers by travellers. Its proprietary algorithm, Virtual Interlining, allows users to combine flights from more than 750 carriers, including many that do not normally cooperate. Kiwi.com also provides its industry-leading Kiwi.com Guarantee, which protects customers from missed connections because of delay, schedule change or cancellation.

Kiwi.com powers more than 100 million flight searches every day and employs over 2,900 people worldwide. It is one of the fastest-growing technology companies in Central Europe. It entered the 2017 Deloitte Technology Fast 500 EMEA list in 7th place, becoming the highest ever ranked Czech company. For the second consecutive year, Kiwi.com was named best Start-up of the Czech Republic by Czech Forbes Magazine in July 2018.

2018 saw the launch of NOMAD, a revolutionary multi-city travel search tool, and Tequila, a B2B platform for partners of all sizes. Also in 2018, Kiwi.com incorporated ground transportation into its search technology.

About General Atlantic

General Atlantic is a leading global growth equity firm providing capital and strategic support for growth companies. Established in 1980, General Atlantic combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to build exceptional businesses worldwide. General Atlantic has more than 150 investment professionals based in New York, Amsterdam, Beijing, Greenwich, Hong Kong, Jakarta, London, Mexico City, Mumbai, Munich, Palo Alto, São Paulo, Shanghai, and Singapore. For more information on General Atlantic, please visit the website: www.generalatlantic.com.

Contact information

Raymond Vrijenhoek
Kiwi.com
raymond.vrijenhoek@kiwi.com

Mary Armstrong & Emily Japlon
General Atlantic
media@generalatlantic.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

 Ipsen to Present New Data at 13th Annual Conference of the International Liver Cancer Association (ILCA 2019)20.9.2019 19:30:00 EESTPress release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today presents results from the matching-adjusted indirect comparison (MAIC) of cabozantinib (Cabometyx®) versus regorafenib (Stivarga®) for the second-line treatment (2L) of patients with advanced hepatocellular carcinoma (aHCC) who received sorafenib as the only prior systemic therapy. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that cabozantinib offers greater efficacy versus regorafenib. Using data from the Phase III CELESTIAL and RESORCE trials, the MAIC showed that in the 2L CELESTIAL sub-population who had received sorafenib as the only prior systemic therapy, cabozantinib significantly improved progression-free survival (PFS), with an additional 2.4 months provided vs. regorafenib (5.6 months vs. 3.2 months [95% confidence interval (CI): 4.90-7.26], p<0.05). Median overall survival (OS) was also favorable with cabozantinib (11.4 months vs. 10.8 months), though statistical significance was not met

RoboSense RS-LiDAR-M1 Smart LiDAR Sensor Wins AutoSens Awards 201920.9.2019 16:30:00 EESTPress release

On September 18, 2019, RoboSense announced at Brussels, Belgium that its flagship product RS-LiDAR-M1 Smart LiDAR Sensor has been awarded the elite AutoSens Awards trophy in the “Best Automotive Safety System” category, given to only the highest-rated innovative product or technology in the automotive industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005309/en/ Robosense Along With Other Winnners At The Autosens Awards Ceremony At Brussels, Belgium (Photo: Business Wire) True autonomous driving requires human-like advanced sensing of the environment for driving with little or no human input. The safety of passengers and passers-by is always the priority concern for autonomous driving. When the RS-LiDAR-M1 is integrated into the current autonomous driving car perception system, it overcomes the weaknesses of millimeter wave radar and camera technologies on identifying obstacles, and eliminates car accidents, such

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases20.9.2019 15:00:00 EESTPress release

Boehringer Ingelheim and Inflammasome Therapeutics Inc. (Inflammasome) today announced they have entered into a co-development and license agreement to develop up to three therapies for patients with retinal diseases. By combining Inflammasome’s unique intravitreal (IVT) drug delivery technologies with Boehringer Ingelheim’s compounds from its retinal disease pipeline portfolio, Boehringer Ingelheim aims to develop novel therapies for retinal diseases. In 2019 there were an estimated 82 million patients in the seven key countries (U.S., Japan, Germany, U.K., Spain, Italy, France) affected by one of the three major forms of retinal disease: Age related macular degeneration (AMD), diabetic retinopathy (DR), and diabetic macular edema (DME). Globally, the prevalence rates of these and other retinal diseases are expected to increase over the next 10 years primarily due to aging populations and the global diabetes epidemic. Despite therapeutic advances in some disease areas during the past

Visa B2B Connect Expands to 32 New Countries and Announces Integration With Infosys20.9.2019 14:00:00 EESTPress release

Visa Inc. (NYSE:V) today announced that its Visa B2B Connect network has doubled its reach – from 30 global trade corridors at launch in June 2019, to 62, with the goal to expand to over 100 countries in 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005082/en/ Visa B2B Connect (Graphic: Business Wire) In addition, Infosys, a global leader in next-generation digital services and consulting, is integrating with the Visa B2B Connect network to bring Visa B2B Connect platform access to their participating financial institutions worldwide. Through this new connection, participating financial institutions worldwide can take advantage of the ability to quickly and securely process corporate cross-border payments globally through Visa B2B Connect.1 “Visa B2B Connect is a fast, secure and more efficient network, designed specifically to overcome obstacles in the cross-border corporate payments space,” said Alan Koenigsbe

Open Day at ISAE-SUPAERO!20.9.2019 12:53:00 EESTPress release

As part of the Science Festival, this year organized on the theme of “Talking about Science, Imagining the Future”, ISAE-SUPAERO will open up its entire campus to the public on Saturday, October 12th from 10 am to 6 pm. Intended for families, companies, partners, journalists and alumni, this event should bring in over 3,000 attendees, as was the case in the three previous years! The program for the day includes many opportunities to discover science today and our vision of the science of the future, with the challenges this entails for the future of our planet. On the program: ➢ Visits to the laboratories and research departments with flight simulators ➢ Visit to the aeroacoustic wind tunnel, unique in Europe, ➢ Demonstrations: how to fly an airplane, Enoskelet, augmented humans, aeroelasticity, drones, use of the gyroscopic effect in space systems, piezoelectric effect, lasers for communicating at the speed of light on Earth and in space, the infinitely small in 3D, Robot Firefighter

William Priest to Step Down as CEO in 2020, Will Remain at Firm as Executive Chairman and Co-CIO20.9.2019 10:00:00 EESTPress release

Epoch Investment Partners, Inc., announced that William Priest will step down as the firm's CEO effective April 1, 2020. He will become Epoch's Executive Chairman and will continue to lead the investment team and serve as co-CIO. He will also retain his portfolio management responsibilities, including his lead portfolio manager role with Epoch's Global Choice and Global Absolute Return strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190920005076/en/ Philipp Hensler (Photo: Business Wire) Philipp Hensler, Epoch's President and COO, will become the firm's CEO. Hensler brings to the role extensive leadership experience at asset management firms globally. His earlier background as a portfolio manager has imbued him with an investment-oriented perspective that aligns with Epoch's investment-centric culture. “Investing remains my lifelong passion," said Priest, who helped found Epoch in 2004. “Best practice suggests a s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom